A股異動 | 康泰生物(300601.SZ)大跌超15% 控股股東524.11萬股將被司法拍賣
格隆匯5月17日丨康泰生物(300601.SZ)跌幅擴大至超15%,報56.02元創2019年8月以來新高價,成交額放大至14.3億元,總市值跌破400億元。公司昨晚公吿,控股股東杜偉民所持公司524.11萬股將被司法拍賣。市場分析人士稱,本次公司控股股東被拍賣股份從數額及流通值佔比上看並不算高。但康泰生物自2020年以來因國家藥品集採股價步入下行通道,在此背景下公司對利空消息更為反應敏感。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.